Kalaris Therapeutics Inc. (KLRS)
KLRS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$2.23
-1.33% on the day
Market cap
$53.1M
Micro cap
Revenue
No annual revenue filed since the period ending 2019-12-31
Net income
No annual revenue filed since the period ending 2019-12-31
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | KLRS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001754068 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
No annual revenue filed since the period ending 2019-12-31.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-04-13 |
| Latest annual report | 10-K | 2026-03-17 |
| Latest quarterly / interim | 10-Q | 2026-08-11 |
| Latest current report | 8-K | 2026-08-11 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 698 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| INKT | MiNK Therapeutics Inc. | $10.23 | -2.85% | $52.2M |
| BKHA | Black Hawk Acquisition Corporation | $12.48 | -4.00% | $51.8M |
| ELOX | Eloxx Pharmaceuticals Inc. | $12.70 | -8.57% | $51.3M |
| CRBU | Caribou Biosciences Inc. | $0.4700 | -5.41% | $50.4M |
| IMA | ImageneBio Inc. | $4.24 | -0.23% | $48.1M |
| INMB | INmune Bio Inc. | $1.68 | -5.62% | $46.6M |
| LONA | LeonaBio Inc. | $6.43 | +4.30% | $60.6M |
| EXOZ | eXoZymes Inc. | $4.59 | -9.11% | $42.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier